A mother and daughter traveled the world searching for children with a genetic disease, NCBRS. Here's why it's nicknamed Beautiful Smile Syndrome.
Big pharma companies are largely exempt, but smaller biotechs are hit hard by Trump's 100% import tax on some prescription drugs.
Neil Carleton, a STAT Wunderkind, is studying whether dialing back treatment in some cases is beneficial for older women with breast cancer.
A startup says waiting for doctors to prescribe, and insurers to pay for, its breast-cancer risk prediction AI would take too long. So its going directly to patients.
Democrats are angling for slots on two powerful House committees that play big roles in health care policy.
The deal between the Swiss company and Defand Therapeutics could signal a shift in global development.
STAT reporters discuss how the NIH has been spending its money and how the unpredictability is impeding U.S. biomedical research.
The world has made great strides in eliminating hepatitis C. But the U.S. remains far behind.
Play: What's the word? Test your knowledge with today's mini crossword
